Geranylgeranyltransferase-1 Inhibitors

Norbert Berndt, Andrew Hamilton, Saïd M. Sebti

Research output: Contribution to journalArticle

Abstract

The ability of many small G-proteins such as RHO and RAL GTPases to contribute to malignant transformation depends on their lipid posttranslational modification by geranylgeranyltransferase-1 (GGT-1). This, coupled with the observation that conditional deletion of GGT-1 compromises KRAS-driven oncogenesis, further spurred interest in the development of GGT-1 inhibitors (GGTIs) as anticancer agents. In this chapter, we describe the development of GGTIs from structure-based drug design to mechanism of action in cultured cells, to antitumor activity in animal models and finally to a recent human phase I clinical trial with GGTI-2418. Highly potent and selective GGTIs inhibit geranylgeranylation of GTPases such as RHOA, CDC42, and RAC1, proteins critical to the G1/S transition of the cell cycle, and induce G1 arrest. This appears to be mediated by induction of p21Cip1, CDK2 and CDK4 inhibition, and RB hypophosphorylation. GGTIs also inhibit CDK2-mediated phosphorylation of p27Kip1 at Thr187, thereby inducing its nuclear accumulation, and this appears to be required for GGTIs ability to induce tumor cell death. Furthermore, suppression of the levels of phospho-Akt, c-FLIP, and survivin as well as induction of death receptors and TRAIL have all been suggested to contribute to GGTIs' ability to induce apoptosis. Extensive work is ongoing to identify proteins whose inhibition of geranylgeranylation contributes toGGTIs' antitumor activity, and the possible involvement of RHOA, RHOC, CDC42, RAC1, RAC3, RALA, and RALB has been suggested.

Original languageEnglish (US)
Pages (from-to)129-163
Number of pages35
JournalEnzymes
Volume30
DOIs
StatePublished - 2011

Fingerprint

Prenylation
GTP Phosphohydrolases
Cells
G1 Phase Cell Cycle Checkpoints
Death Domain Receptors
Clinical Trials, Phase I
Phosphorylation
Monomeric GTP-Binding Proteins
Drug Design
Cell death
Post Translational Protein Processing
Antineoplastic Agents
Tumors
Cultured Cells
Carcinogenesis
Animals
Proteins
Cell Death
Animal Models
Apoptosis

Keywords

  • Anticancer drugs
  • CaaX
  • Drug discovery
  • Genetic mouse model
  • GGTIs
  • Protein prenylation

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Biophysics
  • Molecular Biology

Cite this

Geranylgeranyltransferase-1 Inhibitors. / Berndt, Norbert; Hamilton, Andrew; Sebti, Saïd M.

In: Enzymes, Vol. 30, 2011, p. 129-163.

Research output: Contribution to journalArticle

Berndt, Norbert ; Hamilton, Andrew ; Sebti, Saïd M. / Geranylgeranyltransferase-1 Inhibitors. In: Enzymes. 2011 ; Vol. 30. pp. 129-163.
@article{a7f1d3b72c0640fdb08d1e006fa8aa8d,
title = "Geranylgeranyltransferase-1 Inhibitors",
abstract = "The ability of many small G-proteins such as RHO and RAL GTPases to contribute to malignant transformation depends on their lipid posttranslational modification by geranylgeranyltransferase-1 (GGT-1). This, coupled with the observation that conditional deletion of GGT-1 compromises KRAS-driven oncogenesis, further spurred interest in the development of GGT-1 inhibitors (GGTIs) as anticancer agents. In this chapter, we describe the development of GGTIs from structure-based drug design to mechanism of action in cultured cells, to antitumor activity in animal models and finally to a recent human phase I clinical trial with GGTI-2418. Highly potent and selective GGTIs inhibit geranylgeranylation of GTPases such as RHOA, CDC42, and RAC1, proteins critical to the G1/S transition of the cell cycle, and induce G1 arrest. This appears to be mediated by induction of p21Cip1, CDK2 and CDK4 inhibition, and RB hypophosphorylation. GGTIs also inhibit CDK2-mediated phosphorylation of p27Kip1 at Thr187, thereby inducing its nuclear accumulation, and this appears to be required for GGTIs ability to induce tumor cell death. Furthermore, suppression of the levels of phospho-Akt, c-FLIP, and survivin as well as induction of death receptors and TRAIL have all been suggested to contribute to GGTIs' ability to induce apoptosis. Extensive work is ongoing to identify proteins whose inhibition of geranylgeranylation contributes toGGTIs' antitumor activity, and the possible involvement of RHOA, RHOC, CDC42, RAC1, RAC3, RALA, and RALB has been suggested.",
keywords = "Anticancer drugs, CaaX, Drug discovery, Genetic mouse model, GGTIs, Protein prenylation",
author = "Norbert Berndt and Andrew Hamilton and Sebti, {Sa{\"i}d M.}",
year = "2011",
doi = "10.1016/B978-0-12-415922-8.00006-9",
language = "English (US)",
volume = "30",
pages = "129--163",
journal = "Enzymes",
issn = "0423-2607",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Geranylgeranyltransferase-1 Inhibitors

AU - Berndt, Norbert

AU - Hamilton, Andrew

AU - Sebti, Saïd M.

PY - 2011

Y1 - 2011

N2 - The ability of many small G-proteins such as RHO and RAL GTPases to contribute to malignant transformation depends on their lipid posttranslational modification by geranylgeranyltransferase-1 (GGT-1). This, coupled with the observation that conditional deletion of GGT-1 compromises KRAS-driven oncogenesis, further spurred interest in the development of GGT-1 inhibitors (GGTIs) as anticancer agents. In this chapter, we describe the development of GGTIs from structure-based drug design to mechanism of action in cultured cells, to antitumor activity in animal models and finally to a recent human phase I clinical trial with GGTI-2418. Highly potent and selective GGTIs inhibit geranylgeranylation of GTPases such as RHOA, CDC42, and RAC1, proteins critical to the G1/S transition of the cell cycle, and induce G1 arrest. This appears to be mediated by induction of p21Cip1, CDK2 and CDK4 inhibition, and RB hypophosphorylation. GGTIs also inhibit CDK2-mediated phosphorylation of p27Kip1 at Thr187, thereby inducing its nuclear accumulation, and this appears to be required for GGTIs ability to induce tumor cell death. Furthermore, suppression of the levels of phospho-Akt, c-FLIP, and survivin as well as induction of death receptors and TRAIL have all been suggested to contribute to GGTIs' ability to induce apoptosis. Extensive work is ongoing to identify proteins whose inhibition of geranylgeranylation contributes toGGTIs' antitumor activity, and the possible involvement of RHOA, RHOC, CDC42, RAC1, RAC3, RALA, and RALB has been suggested.

AB - The ability of many small G-proteins such as RHO and RAL GTPases to contribute to malignant transformation depends on their lipid posttranslational modification by geranylgeranyltransferase-1 (GGT-1). This, coupled with the observation that conditional deletion of GGT-1 compromises KRAS-driven oncogenesis, further spurred interest in the development of GGT-1 inhibitors (GGTIs) as anticancer agents. In this chapter, we describe the development of GGTIs from structure-based drug design to mechanism of action in cultured cells, to antitumor activity in animal models and finally to a recent human phase I clinical trial with GGTI-2418. Highly potent and selective GGTIs inhibit geranylgeranylation of GTPases such as RHOA, CDC42, and RAC1, proteins critical to the G1/S transition of the cell cycle, and induce G1 arrest. This appears to be mediated by induction of p21Cip1, CDK2 and CDK4 inhibition, and RB hypophosphorylation. GGTIs also inhibit CDK2-mediated phosphorylation of p27Kip1 at Thr187, thereby inducing its nuclear accumulation, and this appears to be required for GGTIs ability to induce tumor cell death. Furthermore, suppression of the levels of phospho-Akt, c-FLIP, and survivin as well as induction of death receptors and TRAIL have all been suggested to contribute to GGTIs' ability to induce apoptosis. Extensive work is ongoing to identify proteins whose inhibition of geranylgeranylation contributes toGGTIs' antitumor activity, and the possible involvement of RHOA, RHOC, CDC42, RAC1, RAC3, RALA, and RALB has been suggested.

KW - Anticancer drugs

KW - CaaX

KW - Drug discovery

KW - Genetic mouse model

KW - GGTIs

KW - Protein prenylation

UR - http://www.scopus.com/inward/record.url?scp=81255131876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255131876&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-415922-8.00006-9

DO - 10.1016/B978-0-12-415922-8.00006-9

M3 - Article

VL - 30

SP - 129

EP - 163

JO - Enzymes

JF - Enzymes

SN - 0423-2607

ER -